Opsan Healthtech Private Limited

Inj Trastuzumab 150mg is an Injectable formulation containing trastuzumab, a monoclonal antibody that targets HER2 (human epidermal growth factor receptor 2), a protein often overexpressed in certain types of cancer cells, particularly in HER2positive breast cancer and gastric cancer By targeting and inhibiting the activity of HER2, trastuzumab interferes with the signaling pathways that promote cancer cell growth, proliferation, and survival
 Medical Description:
 Generic Name: Trastuzumab   Brand Name: Herceptin (among others) Form: Injectable solution for intravenous (IV) infusion Strength: 150 mg per vial
 Indications:Trastuzumab is primarily used in the treatment of cancers that overexpress the HER2 receptor, including:
1 HER2positive breast cancer:    Earlystage HER2positive breast cancer: Trastuzumab is used as adjuvant therapy to reduce the risk of recurrence after surgery    Metastatic HER2positive breast cancer: Used either as a monotherapy or in combination with other chemotherapy or targeted therapies
2 HER2positive metastatic gastric or gastroesophageal junction cancer:    Used in combination with chemotherapy for the treatment of HER2positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma
 Mechanism of Action:Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the HER2 receptor The HER2 receptor is involved in cellular signaling pathways that regulate growth, differentiation, and survival In cancers where HER2 is overexpressed, these pathways can become dysregulated, leading to uncontrolled cell proliferation
Trastuzumab works through several mechanisms: Blocking HER2 signaling: It prevents the activation of downstream signaling pathways that promote cell growth and survival Inducing antibodydependent cellular cytotoxicity (ADCC): It recruits immune cells to target and destroy cancer cells Inhibiting angiogenesis: It reduces the formation of new blood vessels that tumors need to grow and spread
 Administration: Route: Trastuzumab is administered as an intravenous (IV) infusion Dosing:   Loading dose: 8 mg/kg of body weight as the first dose (typically in the initial infusion)   Maintenance dose: After the loading dose, 6 mg/kg of body weight is typically administered every 3 weeks as a maintenance infusion This is the most common regimen for patients with metastatic HER2positive breast cancer   The 150 mg vial may be used as part of a fixeddose regimen for certain patients, typically after an initial loading dose has been given, depending on the patient's body weight
 The infusion time may vary:   For the first infusion, it is typically administered over 90 minutes   Subsequent infusions may be administered over 3060 minutes, depending on the patient's tolerance
 Side Effects: Common Side Effects:   Fever or chills   Fatigue   Nausea   Diarrhea   Pain at the Injection site   Headaches   Rash or skin reactions   Serious Side Effects:   Cardiotoxicity: Trastuzumab can cause heart failure and left ventricular dysfunction, particularly in patients with preexisting heart conditions Cardiac monitoring, including echocardiograms, is recommended before starting therapy and during treatment   Infusionrelated reactions: Symptoms can include fever, chills, nausea, headache, low blood pressure, and in rare cases, anaphylaxis Infusionrelated reactions are more common with the first infusion   Pulmonary toxicity: Interstitial lung disease or pneumonitis can occur, leading to shortness of breath, cough, and fever   Neutropenia (low white blood cell count), which may increase the risk of infections

Epoetin Alfa Injection: Medical Overview

Epoetin alfa is a synthetic form of erythropoietin, a hormone naturally produced by the kidneys that stimulates red blood cell production in the bone marrow. It is used to treat anemia associated with chronic kidney disease (CKD), chemotherapy, and certain other conditions.

-

Indications

Epoetin alfa is prescribed for:

Anemia due to Chronic Kidney Disease (CKD): In both dialysis and non-dialysis patients.

Anemia from Chemotherapy: In patients receiving myelosuppressive chemotherapy.
Anemia from HIV Treatment: In patients receiving zidovudine therapy.

Preoperative Anemia: To reduce the need for allogeneic red blood cell transfusions in patients undergoing elective, non-cardiac, non-vascular surgery.
-

Mechanism of Action

Epoetin alfa stimulates erythropoiesis (red blood cell production) by binding to and activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells.

-

Dosage and Administration

Route: Administered via subcutaneous (SC) injection or intravenous (IV) infusion.

Dosing: The dosage varies based on the patient's condition, response to treatment, and hemoglobin levels. Regular monitoring is essential to adjust dosing appropriately.

Administration: Typically administered by a healthcare professional. If self-administration is prescribed, proper training on injection techniques is required.

-

Contraindications and Precautions

Epoetin alfa is contraindicated in:

Patients with uncontrolled hypertension.

Known hypersensitivity to epoetin alfa or any of its components.

Patients with pure red cell aplasia due to previous epoetin alfa therapy.([Practo][2])

Use with caution in:

Patients with a history of seizures.

Individuals with cardiovascular disease or risk factors.

Patients with iron deficiency, as adequate iron levels are necessary for optimal response.

Regular monitoring of blood pressure, hemoglobin levels, and iron status is recommended during therapy.

-

Side Effects

Common side effects include:

Headache

Hypertension([Mayo Clinic][3])

Injection site reactions

Fatigue

Nausea

Serious adverse effects may include:

Severe allergic reactions (e.g., anaphylaxis)

Seizures([Cleveland Clinic][4])

Thromboembolic events (e.g., stroke, myocardial infarction)

Pure red cell aplasia

Discontinue therapy and seek immediate medical attention if any of these serious side effects occur.

-

Pharmacokinetics

Absorption: Epoetin alfa is well absorbed following subcutaneous injection.

Distribution: Widely distributed in the body.

Metabolism: Metabolized primarily in the liver.

Elimination: Excreted via the urine.

-

Price and Availability

The cost of epoetin alfa varies based on brand, dosage, and location. Common brands include Epogen® and Procrit®. Prices may differ between countries and healthcare providers. It's advisable to consult local pharmacies or healthcare providers for specific pricing information.

-